↓ Skip to main content

Heart Failure

Overview of attention for book
Cover of 'Heart Failure'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 13 Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction
  3. Altmetric Badge
    Chapter 23 Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications
  4. Altmetric Badge
    Chapter 24 Heart Failure Guidelines on Pharmacotherapy
  5. Altmetric Badge
    Chapter 25 Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders
  6. Altmetric Badge
    Chapter 27 Comorbidities in Heart Failure
  7. Altmetric Badge
    Chapter 28 Vasopressin and Vasopressin Antagonists in Heart Failure
  8. Altmetric Badge
    Chapter 30 Iron Deficiency Treatment in Patients with Heart Failure
  9. Altmetric Badge
    Chapter 31 Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction
  10. Altmetric Badge
    Chapter 55 Ivabradine.
  11. Altmetric Badge
    Chapter 56 Wnt Signaling in Cardiac Remodeling and Heart Failure
  12. Altmetric Badge
    Chapter 74 Epidemiology of Heart Failure
  13. Altmetric Badge
    Chapter 75 Clinical Trial Design, Endpoints, and Regulatory Requirements
  14. Altmetric Badge
    Chapter 76 Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
  15. Altmetric Badge
    Chapter 77 Sacubitril/Valsartan (LCZ696) in Heart Failure
  16. Altmetric Badge
    Chapter 80 Platelet-Derived Growth Factor in Heart Failure
  17. Altmetric Badge
    Chapter 81 Gene Therapy in Heart Failure
  18. Altmetric Badge
    Chapter 82 Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease
  19. Altmetric Badge
    Chapter 83 Partial Adenosine A1 Agonist in Heart Failure
  20. Altmetric Badge
    Chapter 86 Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction
  21. Altmetric Badge
    Chapter 88 New and Emerging Therapies and Targets: Beta-3 Agonists
  22. Altmetric Badge
    Chapter 99 Noncoding RNAs in Heart Failure
  23. Altmetric Badge
    Chapter 100 Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure
  24. Altmetric Badge
    Chapter 101 The Three-Decade Long Journey in Heart Failure Drug Development
  25. Altmetric Badge
    Chapter 123 Mitochondrial Therapies in Heart Failure
  26. Altmetric Badge
    Chapter 126 Anticoagulation Therapy and NOACs in Heart Failure
Attention for Chapter 27: Comorbidities in Heart Failure
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
105 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Comorbidities in Heart Failure
Chapter number 27
Book title
Heart Failure
Published in
Handbook of experimental pharmacology, April 2017
DOI 10.1007/164_2017_27
Pubmed ID
Book ISBNs
978-3-31-959658-7, 978-3-31-959659-4
Authors

van der Wal, Haye H., van Deursen, Vincent M., van der Meer, Peter, Voors, Adriaan A., Haye H. van der Wal, Vincent M. van Deursen, Peter van der Meer, Adriaan A. Voors, Wal, Haye H., Deursen, Vincent M., Meer, Peter

Abstract

Comorbidities frequently accompany chronic heart failure (HF), contributing to increased morbidity and mortality, and an impaired quality of life. We describe the prevalence of several high-impact comorbidities in chronic HF patients and their impact on morbidity and mortality. Furthermore, we try to explain the underlying pathophysiological processes and the complex interaction between chronic HF and specific comorbidities. Although common risk factors are likely to contribute, it is reasonable to believe that factors associated with HF might cause other comorbidities and vice versa. Potential factors are inflammation, neurohormonal activation, and hemodynamic changes.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 105 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 16 15%
Researcher 13 12%
Student > Master 10 10%
Other 9 9%
Student > Ph. D. Student 9 9%
Other 14 13%
Unknown 34 32%
Readers by discipline Count As %
Medicine and Dentistry 37 35%
Nursing and Health Professions 7 7%
Neuroscience 5 5%
Psychology 4 4%
Biochemistry, Genetics and Molecular Biology 4 4%
Other 13 12%
Unknown 35 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 December 2022.
All research outputs
#4,290,930
of 23,306,612 outputs
Outputs from Handbook of experimental pharmacology
#134
of 649 outputs
Outputs of similar age
#75,580
of 310,364 outputs
Outputs of similar age from Handbook of experimental pharmacology
#3
of 10 outputs
Altmetric has tracked 23,306,612 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 649 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,364 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.